Instructions for LAFRAX (Ofloxacin)
Short description LAFRAX:
Antibacterial agent of the second generation fluoroquinolone group.
pharmachologic effect LAFRAX:
Pharmacological action - antibacterial, bactericidal. Inhibits DNA gyrase (topoisomerase II and IV), disrupts the process of supercoiling and stitching of DNA breaks, inhibits cell division, causes structural changes in the cytoplasm and the death of microorganisms. Has a wide range of effects. Affects mainly gram-negative and some gram-positive microorganisms. Effective against microorganisms resistant to most antibiotics and sulfa drugs. Cross-resistance of bacteria to ofloxacin and other fluoroquinolones is possible.
The spectrum of action includes: E. coli, Salmonella spp., Enterobacter spp., Serratia spp., Citrobacter spp., Yersinia spp., Haemophilus influenzae, Haemophilus ducreyi, Proteus mirabilis, Proteus vulgaris, Pseudomonas spp., Incl. Pseudomonas aeruginosa, Acinetobacter spp., Aeromonas hydrophilia, Bordetella parapertussis, Bordetella pertussis, Klebsiella spp., Incl. Klebsiella pneumoniae, Moraxella (Branhamella) catarrhalis, Morganella morganii, Providencia spp., Neisseria gonorrhoeae, Neisseria meningitidis, Shigella sonnei, Helicobacter pylori, Mycoplasma spp., Ureaplasma uibrealytic spp., Ureaplasma uibrealytic spp., Ureaplasma uibrealytic spp. spp., Streptococcus spp., Enterococcus faecalis, Listeria monocytogenes, Propionibacterium acnes, Clostridium perfringens, Mycobacterium tuberculosis (including multi-resistant strains). When taken orally, it is completely absorbed from the gastrointestinal tract (about 95%), absolute bioavailability? 96%. After taking ofloxacin in the dosage form of conventional tablets, Cmax in plasma is reached after 1--2 hours, after taking extended-release tablets? within 6–8 hours.
Plasma protein binding? 32%. The apparent volume of distribution is 100 liters. T1 / 2 with regular pills? 4.5-7 hours Penetrates into cells (leukocytes, alveolar macrophages) of most organs and tissues, creates high concentrations in urine, bile, saliva, sputum, prostate secretions, kidneys, liver, gall bladder, skin, lungs, passes through BBB and placental barrier. In the liver (about 5%) is converted into N-oxide ofloxacin and demethylofloxacin. It is excreted mainly by the kidneys unchanged (80–90%); a small part is excreted in bile, feces, breast milk (extrarenal clearance is less than 20%). After a single oral administration of 200 mg in urine is detected within 20–24 hours. In liver and / or kidney diseases, excretion may slow down.
Indications LAFRAX:
In ophthalmology:
bacterial corneal ulcers
conjunctivitis
blepharitis
meibomitis
dacryocystitis
keratitis
chlamydial eye infections
prevention of infectious complications in the postoperative period after surgery for removal of a foreign body and eye injury.
Side effects LAFRAX:
When used in ophthalmology: burning sensation and discomfort in the eyes, redness, itching and dryness of the conjunctiva, photophobia, lacrimation; seldom ? dizziness, nausea.
Contraindications LAFRAX:
For local forms: chronic non-bacterial conjunctivitis or otitis media.
Overdose LAFRAX:
Symptoms:
drowsiness
nausea
vomiting
dizziness
disorientation
lethargy
confusion
Treatment: gastric lavage, maintenance of vital functions.
special instructions LAFRAX:
Should not be injected subconjunctivally or injected into the anterior chamber of the eye.
When using ophthalmic forms, it is not recommended to wear eye lenses.
The combined use of eye drops and eye ointment is possible, with the ointment being used last.
Interaction with other drugs LAFRAX
Antacids containing Al3 +, Ca2 +, Mg2 +, iron salts, saline laxatives, sucralfate, zinc reduce absorption and reduce activity (the interval between doses should be at least 2 hours). With the concomitant use of NSAIDs and quinolones (including ofloxacin), the risk of CNS stimulation and the development of seizures may increase. With the simultaneous administration of ofloxacin with theophylline, T1 / 2 can be prolonged and the Css of theophylline can increase, as a result of which the risk of theophylline toxicity increases. Furosemide and methotrexate inhibit excretion and may increase toxicity. Increases the concentration of glibenclamide. Do not mix with heparin in solution (risk of precipitation).
